@article{HindererShenRinguetteetal.2015,
  author    = {Hinderer, Svenja and Shen, Nian and Ringuette, L{\´e}a-Jeanne and Hansmann, Jan and Reinhardt, Dieter P and Brucker, Sara Y and Davis, Elaine C and Schenke-Layland, Katja},
  title     = {In vitro elastogenesis: instructing human vascular smooth muscle cells to generate an elastic fiber-containing extracellular matrix scaffold},
  series = {Biomedical Materials},
  volume    = {10},
  journal   = {Biomedical Materials},
  number    = {3},
  doi       = {10.1088/1748-6041/10/3/034102},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-254074},
  year      = {2015},
  abstract  = {Elastic fibers are essential for the proper function of organs including cardiovascular tissues such as heart valves and blood vessels. Although (tropo)elastin production in a tissue-engineered construct has previously been described, the assembly to functional elastic fibers in vitro using human cells has been highly challenging. In the present study, we seeded primary isolated human vascular smooth muscle cells (VSMCs) onto 3D electrospun scaffolds and exposed them to defined laminar shear stress using a customized bioreactor system. Increased elastin expression followed by elastin deposition onto the electrospun scaffolds, as well as on newly formed fibers, was observed after six days. Most interestingly, we identified the successful deposition of elastogenesis-associated proteins, including fibrillin-1 and -2, fibulin-4 and -5, fibronectin, elastin microfibril interface located protein 1 (EMILIN-1) and lysyl oxidase (LOX) within our engineered constructs. Ultrastructural analyses revealed a developing extracellular matrix (ECM) similar to native human fetal tissue, which is composed of collagens, microfibrils and elastin. To conclude, the combination of a novel dynamic flow bioreactor and an electrospun hybrid polymer scaffold allowed the production and assembly of an elastic fiber-containing ECM.},
  language  = {en}
}
@article{AlepeeBahinskiDaneshianetal.2014,
  author    = {Alepee, Natalie and Bahinski, Anthony and Daneshian, Mardas and De Weyer, Bart and Fritsche, Ellen and Goldberg, Alan and Hansmann, Jan and Hartung, Thomas and Haycock, John and Hogberg, Helena T. and Hoelting, Lisa and Kelm, Jens M. and Kadereit, Suzanne and McVey, Emily and Landsiedel, Robert and Leist, Marcel and L{\"u}bberstedt, Marc and Noor, Fozia and Pellevoisin, Christian and Petersohn, Dirk and Pfannenbecker, Uwe and Reisinger, Kerstin and Ramirez, Tzutzuy and Rothen-Rutishauser, Barbara and Sch{\"a}fer-Korting, Monika and Zeilinger, Katrin and Zurich, Marie-Gabriele},
  title     = {State-of-the-Art of 3D Cultures (Organs-on-a-Chip) in Safety Testing and Pathophysiology},
  series = {ALTEX - Alternatives to Animal Experimentation},
  volume    = {31},
  journal   = {ALTEX - Alternatives to Animal Experimentation},
  number    = {4},
  doi       = {2014; http://dx.doi.org/10.14573/altex1406111},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-117826},
  pages     = {441-477},
  year      = {2014},
  abstract  = {Integrated approaches using different in vitro methods in combination with bioinformatics can (i) increase the success rate and speed of drug development; (ii) improve the accuracy of toxicological risk assessment; and (iii) increase our understanding of disease. Three-dimensional (3D) cell culture models are important building blocks of this strategy which has emerged during the last years. The majority of these models are organotypic, i.e., they aim to reproduce major functions of an organ or organ system. This implies in many cases that more than one cell type forms the 3D structure, and often matrix elements play an important role. This review summarizes the state of the art concerning commonalities of the different models. For instance, the theory of mass transport/metabolite exchange in 3D systems and the special analytical requirements for test endpoints in organotypic cultures are discussed in detail. In the next part, 3D model systems for selected organs liver, lung, skin, brain are presented and characterized in dedicated chapters. Also, 3D approaches to the modeling of tumors are presented and discussed. All chapters give a historical background, illustrate the large variety of approaches, and highlight up- and downsides as well as specific requirements. Moreover, they refer to the application in disease modeling, drug discovery and safety assessment. Finally, consensus recommendations indicate a roadmap for the successful implementation of 3D models in routine screening. It is expected that the use of such models will accelerate progress by reducing error rates and wrong predictions from compound testing.},
  language  = {en}
}